Foghorn Therapeutics Reports Q1 Results, Highlights Strong Pipeline Progress and Extended Cash Runway

summarizeSummary

Foghorn Therapeutics reported Q1 2026 results with a strong cash position extending its runway into H1 2028, alongside significant positive updates on its lead clinical program FHD-909 and three advancing preclinical degrader programs.

check_boxKey Events

• Extended Cash Runway

  The company reported $183.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a cash runway into the first half of 2028.

• Lead Program FHD-909 Progress

  Preclinical data for FHD-909 in combination with an anti-PD-1 antibody demonstrated complete, durable tumor regression and anti-tumor immune memory, with plans to evaluate combination studies in front-line NSCLC.

• Degrader Pipeline Advancement

  Three wholly-owned degrader programs (Selective CBP, EP300, and ARID1B) are advancing, with INDs anticipated in 2027 for CBP and EP300 degraders, and in vivo proof-of-concept in 2026 for the ARID1B degrader.

• Mixed Q1 Financials

  Collaboration revenue decreased to $3.3 million from $6.0 million year-over-year, and net loss increased to $19.9 million from $18.8 million.

auto_awesomeAnalysis

This 8-K filing, accompanying the Q1 2026 earnings report, provides extensive positive updates on Foghorn Therapeutics' clinical and preclinical pipeline. While collaboration revenue decreased and net loss increased, the company reported a strong cash position of $183.6 million, extending its runway into the first half of 2028. Key highlights include significant preclinical data for the lead program FHD-909 in combination with an anti-PD-1 antibody, demonstrating durable tumor regression and immune memory, with plans to evaluate combination studies in front-line NSCLC. Additionally, three wholly-owned degrader programs (Selective CBP, EP300, and ARID1B) are advancing with anticipated INDs in 2027 or in vivo proof-of-concept in 2026, showcasing robust anti-tumor activity and improved tolerability profiles. These detailed operational advancements are critical for a clinical-stage biotechnology company and provide a positive outlook despite mixed quarterly financials.